SLC27A3: A Potential Drug Target and Biomarker for Fatty Acid Oxidation

Target Name: SLC27A3

NCBI ID: G11000

SLC27A3

SLC27A3: A Potential Drug Target and Biomarker for Fatty Acid Oxidation

Fatty acid oxidation is a critical process for maintaining cellular health and metabolism. It is a metabolic pathway that generates energy in the form of ATP and eliminates toxic byproducts. The long-chain fatty acids (LCFAs) are an essential part of this pathway, and their efficient metabolism is crucial for overall health. SLC27A3, a protein encoded in the SLC27A3 gene, is a key enzyme in the synthesis of LCFAs from tryptophan, a critical amino acid for protein synthesis. In this article, we will discuss SLC27A3 as a drug target and biomarker for fatty acid oxidation.

SLC27A3: Structure and Function

SLC27A3 is a 27-kDa protein that belongs to the Superfamily A, member 27 (SFAM27) of the Asparagine-Aspartate (Asp-Asp) domain containing proteins. It is expressed in various tissues and cells, including liver, muscle, and fat cells, making it an attractive drug target for therapies targeting fatty acid oxidation.

SLC27A3 functions as a ligase for the conversion of tryptophan (Try) to 4-oxo-linoleic acid (4-LOA) via a series of intermediate steps. The tryptophan molecule is a key precursor for the synthesis of LCFAs, and its conversion to 4-LOA is the first step in the synthesis of these essential fatty acids. SLC27A3 catalyzes the conversion by catalyzing the transfer of a phosphate group from ATP to the 4'-end of the tryptophan molecule. This conversion is critical for the synthesis of LCFAs, as the availability of tryptophan determines the rate of 4-LOA synthesis and the rate of fatty acid oxidation.

SLC27A3 has been shown to be involved in various cellular processes, including energy metabolism, inflammation, and stress resistance. It has been shown to regulate the levels of tryptophan in the brain, muscle, and liver, as well as its metabolism to 4-LOA. SLC27A3 has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway.

Drug Targeting SLC27A3

SLC27A3 is a potential drug target for treating various diseases associated with fatty acid oxidation disorders. One of the main therapeutic targets for SLC27A3 is the treatment of obesity and type 2 diabetes, which are associated with disruptions in fatty acid oxidation.

Obesity is a major risk factor for the development of various diseases, including cardiovascular disease, diabetes, and certain cancers. Disruptions in fatty acid oxidation have been shown to contribute to the development and progression of these diseases. SLC27A3 has been shown to be involved in the regulation of tryptophan metabolism, which is a critical step in the synthesis of LCFAs. Therefore, targeting SLC27A3 with drugs that promote tryptophan metabolism and enhance fatty acid oxidation could be an effective strategy for the treatment of obesity and type 2 diabetes.

Another potential therapeutic target for SLC27A3 is the treatment of inflammation. SLC27A3 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of inflammation and has been implicated in the development of various inflammatory diseases, including obesity and type 2 diabetes. Targeting SLC27A3 with drugs that enhance TGF-β signaling and regulate inflammation could be an effective strategy for the treatment of these diseases.

Biomarker SLC27A3

SLC27A3 has also been shown to be involved in

Protein Name: Solute Carrier Family 27 Member 3

Functions: Mainly functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates (PubMed:23936004). Can mediate the levels of long-chain fatty acids (LCFA) in the cell by facilitating their transport across membranes (By similarity)

The "SLC27A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC27A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets